glp 1 agonist retatrutide 🎙️ NEW EPISODE: Retatrutide—The Triple *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in The power of three: Retatrutide's
Description
[10] It is currently in clinical development
This is an industry, where when you have the patent and you are able to make an N of one drug, we're not quite seeing an N of one drug here, but it's an N of two drug, you get the profits
van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, Nieuwdorp M, Hoogenberg K, van Raalte DH, et al
This is exactly where the right support makes all the difference
Mounjaro users achieve greater average weight loss (18.4%) than those using Wegovy (14.9%) and Ozempic (15%)
